Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.34 |
| ▸ | FPR2 | P25090 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4727194 | 0.80 | CNR2 (0.46) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4727008 | 0.80 | CNR2 (0.46) | NPC1MEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL4728914 | 0.78 | RAB9A (0.51) | NPC1P2RX7MEN1KMT2AKDM4E | |
| SCHEMBL4731777 | 0.78 | RAB9A (0.51) | NPC1P2RX7MEN1KMT2AKDM4E | |
| SCHEMBL6091141 | 0.75 | FAAH (0.49) | NPC1P2RX7MEN1KMT2AKDM4E | |
| SCHEMBL18595247 | 0.73 | P2RX7 (0.51) | NPC1P2RX7MEN1KMT2AGRM5 | |
| SCHEMBL2638097 | 0.72 | NPC1 (0.56) | NPC1GBA1P2RX7GRM5KDM4E | |
| SCHEMBL1769995 | 0.71 | TSHR (0.56) | P2RX7MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL4728169 | 0.71 | TSHR (0.56) | P2RX7MEN1KMT2AALDH1A1TP53 | |
| SCHEMBL5505975 | 0.71 | MEN1 (0.58) | NPC1MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | claimed |
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074083-A1 | Cyclic and acyclic propenones for treating CNS disorders | PMP22, ADCYAP1R1, CYP11B2 | NPC1 245/4885GBA1 190/4885P2RX7 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.